Reperfusion Treatment Market Size and Trends

Reperfusion Treatment MarketSize and Trends

The global reperfusion treatment market is estimated to be valued at US$ 1,546.7 Million in 2023 and is expected to exhibit a CAGR of 4.7% during the forecast period (2023-2030).

Figure 1. Global Reperfusion Treatment Market Share (%), By Injury Type, 2023

Global Reperfusion Treatment Market– Drivers

Increasing research and development activities related to perfusion treatment

Increasing research and development in the field of perfusion treatment is expected to drive the global reperfusion treatment market growth over the forecast period. For instance, on June 27, 2023, Society of Nuclear Medicine and Molecular Imaging, a journal published an article explaining how a novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity as compared to 99mTc-SPECT myocardial perfusion imaging (MPI). 18F-flurpiridaz PET MPI performed as well in patients with and without obesity while producing images at a lower radiation dosage than 99mTc-SPECT MPI. Obese people frequently suffer from illnesses like diabetes, high cholesterol, and high blood pressure thatincrease their risk of developing CAD. Imaging obese patients for CAD is crucial due to these risk factors.

Figure 2. Global Reperfusion Treatment Market Share (US$ Million), By Region, 2023

Global Reperfusion Treatment Market- Segmentation

The global reperfusion treatment market report is segmented into treatment type, injury type, distribution channel and region.

Based on treatment type, the global reperfusion treatment market is segmented into therapeutic hypothermia, cyclosporin, stem cell therapy, hydrogen sulphide treatment, and others. Out of which, the stem cell therapy segment is expected to dominate the market due to increasing research and development for advance stem cell therapy.

Based on injury type, the global reperfusion treatment market is segmented into heart injury, kidney injury, intestine injury, and others. Among these, the heart injury segment is expected to dominate the market over the forecast period due to the increasing demand for perfusion treatment in various injury type.

Based on distribution channel, the global reperfusion treatment market is segmented into hospital pharmacies, retail pharmacies, and others. Among these, hospital pharmacies are expected to dominate the market over the forecast period due to advanced facilities for providing treatments in hospital.

Based on Region, the global reperfusion treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Among these, North America is expected to dominate the market due to increasing research and development activities in the region.

Among all segmentation, the treatment type segment has the highest potential due to the increasing research and development for therapeutic Hypothermia. For instance, on July 14, 2021, an article published by Open Urology and Nephrology Journal explained that the administration of Bacillus Calmette-Guérin (BCG) perfusion therapy for CIS of the upper urinary tract (UUT). Radial nephroureterectomy with bladder cuff excision is the recommended course of treatment for UUT urothelium carcinoma (UC). But in patients with risk factors like bilateral tumors, cardiovascular morbidity, and chronic renal failure, nephron-sparing methods are preferred. Antegrade perfusion via nephrostomy and retrograde perfusion by using a ureteric catheter or double-J ureteric stent are the two available administration methods.

Global Reperfusion Treatment Market- Cross Sectional Analysis:

Key market participants in the Europe region are projected to introduce novel therapies and technologies in perfusion therapy, which will fuel the growth of the treatment sector in the area. For instance, on May 14, 2020, Dove Press Ltd, a global publisher, published an article explaining that acardiac malformation, also known as twin reversed arterial perfusion (TRAP) sequence, is a rare complication of monochorionic multiple pregnancy in which "acardic" (lacks a complete cardiac structure), while the other twin, the "pump twin," supplies both circulations.